Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00752219 · ClinicalTrials.gov registry record · Phase 2
Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 204
- Enrollment target
NCT00752219 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 204 participants.
The verdict
NCT00752219, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 204 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.
Interventions
- DRUG meropenem
- DRUG ceftazidime/NXL104 + metronidazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2009-03-31 |
| Est. Completion | 2009-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00752219
The ClinicalTrials.gov registry entry for NCT00752219 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which meropenem is the first listed.
NCT00752219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00752219 about?
NCT00752219 is a clinical study titled "Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections". The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.
What is the current status of trial NCT00752219?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2009-03-31. Estimated completion is 2009-12-31.
What interventions are being tested in trial NCT00752219?
The interventions under investigation include: meropenem (DRUG), ceftazidime/NXL104 + metronidazole (DRUG).
Who is sponsoring clinical trial NCT00752219?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.